Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Pliant Therapeutics Inc shares valued at $587,150 were sold by Coulie Bernard on Jan 17 ’25. At $11.20 per share, Coulie Bernard sold 52,419 shares. The insider’s holdings dropped to 430,517 shares worth approximately $0.61 million following the completion of this transaction.
Also, Cummings Keith Lamont sold 20,148 shares, netting a total of over 225,680 in proceeds. Following the sale of shares at $11.20 each, the insider now holds 262,608 shares.
Before that, Hull Hans had sold 15,936 shares from its account. In a trade valued at $178,501, the Chief Business Officer traded Pliant Therapeutics Inc shares for $11.20 each. Upon closing the transaction, the insider’s holdings decreased to 15,936 shares, worth approximately $0.3 million.
Analysts at Needham downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in early March. As of March 03, 2025, Stifel has decreased its “Buy” rating to a “Hold” for PLRX. Earlier on March 03, 2025, Leerink Partners downgraded its rating. Their new recommendation was “a Market perform” for PLRX stock which previously was a “an Outperform”.
Analyzing PLRX Stock Performance
On last trading session,, Pliant Therapeutics Inc [NASDAQ: PLRX] rose 5.97% to $1.42. The stock’s lowest price that day was $1.33, but it reached a high of $1.4791 in the same session. During the last five days, there has been a surge of approximately 1.43%. Over the course of the year, Pliant Therapeutics Inc shares have dropped approximately -89.27%.
Support And Resistance Levels for Pliant Therapeutics Inc (PLRX)
RSI (Relative Strength Index) is 54.74 on the 14-day chart, showing neutral technical sentiment.
Is Pliant Therapeutics Inc subject to short interest?
Stocks of Pliant Therapeutics Inc saw a sharp steep in short interest on 2025-06-13 dropping by -1.67 million shares to 3.36 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 5.04 million shares. A decline of -49.73% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.14 of the overall float, the days-to-cover ratio (short ratio) decline to 3.14.
Which companies own the most shares of Pliant Therapeutics Inc (PLRX)?
In terms of Pliant Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 2.5 in the next 12 months, up nearly 86.57% from the previous closing price of $1.34. Analysts anticipate Pliant Therapeutics Inc stock to reach 3 by 2025, with the lowest price target being 2. In spite of this, 5 analysts ranked Pliant Therapeutics Inc stock as Buy at the end of 2025. On February 10, 2025, Wells Fargo assigned a price target of “an Equal weight” to the stock and downgraded coverage with a $4.
